AbbVie Inc. (ABBV)
USD 173.02
(-1.35%)
USD 173.02
(-1.35%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 52.19 Billion USD | -11.74% |
| 2022 | 59.13 Billion USD | -7.87% |
| 2021 | 64.18 Billion USD | -17.23% |
| 2020 | 77.55 Billion USD | 23.15% |
| 2019 | 62.97 Billion USD | 79.92% |
| 2018 | 35 Billion USD | 13.08% |
| 2017 | 30.95 Billion USD | -15.06% |
| 2016 | 36.44 Billion USD | 24.62% |
| 2015 | 29.24 Billion USD | 176.76% |
| 2014 | 10.56 Billion USD | -26.08% |
| 2013 | 14.29 Billion USD | -2.31% |
| 2012 | 14.63 Billion USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 58.04 Billion USD | -9.02% |
| 2024 Q1 | 63.8 Billion USD | 22.25% |
| 2024 Q3 | 58.5 Billion USD | 0.79% |
| 2023 Q1 | 59.29 Billion USD | 0.27% |
| 2023 Q2 | 55.81 Billion USD | -5.87% |
| 2023 FY | 52.19 Billion USD | -11.74% |
| 2023 Q3 | 55.63 Billion USD | -0.32% |
| 2023 Q4 | 52.19 Billion USD | -6.18% |
| 2022 Q2 | 61 Billion USD | -3.97% |
| 2022 FY | 59.13 Billion USD | -7.87% |
| 2022 Q4 | 59.13 Billion USD | -2.09% |
| 2022 Q3 | 60.39 Billion USD | -0.99% |
| 2022 Q1 | 63.52 Billion USD | -1.04% |
| 2021 Q1 | 74.18 Billion USD | -4.35% |
| 2021 FY | 64.18 Billion USD | -17.23% |
| 2021 Q2 | 74.23 Billion USD | 0.07% |
| 2021 Q3 | 74.04 Billion USD | -0.25% |
| 2021 Q4 | 64.18 Billion USD | -13.32% |
| 2020 Q2 | 82.06 Billion USD | 29.67% |
| 2020 Q3 | 82.28 Billion USD | 0.27% |
| 2020 Q4 | 77.55 Billion USD | -5.75% |
| 2020 FY | 77.55 Billion USD | 23.15% |
| 2020 Q1 | 63.28 Billion USD | 0.49% |
| 2019 Q2 | 31.61 Billion USD | -9.83% |
| 2019 Q4 | 62.97 Billion USD | 90.11% |
| 2019 FY | 62.97 Billion USD | 79.92% |
| 2019 Q1 | 35.06 Billion USD | 0.18% |
| 2019 Q3 | 33.12 Billion USD | 4.77% |
| 2018 Q2 | 30.57 Billion USD | -1.06% |
| 2018 FY | 35 Billion USD | 13.08% |
| 2018 Q4 | 35 Billion USD | -4.07% |
| 2018 Q3 | 36.48 Billion USD | 19.32% |
| 2018 Q1 | 30.9 Billion USD | -0.15% |
| 2017 Q3 | 33.97 Billion USD | 0.46% |
| 2017 Q4 | 30.95 Billion USD | -8.89% |
| 2017 Q1 | 36.52 Billion USD | 0.24% |
| 2017 Q2 | 33.81 Billion USD | -7.42% |
| 2017 FY | 30.95 Billion USD | -15.06% |
| 2016 Q1 | 29.49 Billion USD | 0.85% |
| 2016 FY | 36.44 Billion USD | 24.62% |
| 2016 Q3 | 37.28 Billion USD | -0.12% |
| 2016 Q4 | 36.44 Billion USD | -2.26% |
| 2016 Q2 | 37.32 Billion USD | 26.58% |
| 2015 Q2 | 27.11 Billion USD | 153.82% |
| 2015 FY | 29.24 Billion USD | 176.76% |
| 2015 Q1 | 10.68 Billion USD | 1.12% |
| 2015 Q4 | 29.24 Billion USD | -6.76% |
| 2015 Q3 | 31.35 Billion USD | 15.65% |
| 2014 Q3 | 14.46 Billion USD | -0.01% |
| 2014 Q4 | 10.56 Billion USD | -26.98% |
| 2014 Q2 | 14.47 Billion USD | 0.58% |
| 2014 Q1 | 14.38 Billion USD | 0.66% |
| 2014 FY | 10.56 Billion USD | -26.08% |
| 2013 FY | 14.29 Billion USD | -2.31% |
| 2013 Q1 | 14.6 Billion USD | -0.2% |
| 2013 Q2 | 14.32 Billion USD | -1.88% |
| 2013 Q3 | 14.37 Billion USD | 0.34% |
| 2013 Q4 | 14.29 Billion USD | -0.58% |
| 2012 FY | 14.63 Billion USD | 0.0% |
| 2012 Q4 | 14.63 Billion USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bristol-Myers Squibb Company | 38.18 Billion USD | -36.694% |
| Bristol-Myers Squibb Company Ce | 38.18 Billion USD | -36.694% |
| Johnson & Johnson | 25.88 Billion USD | -101.669% |
| Eli Lilly and Company | 18.32 Billion USD | -184.889% |
| Merck & Co., Inc. | 33.68 Billion USD | -54.957% |
| Novartis AG | 20.03 Billion USD | -160.527% |
| Organon & Co. | 8.75 Billion USD | -496.435% |
| Pfizer Inc. | 61.53 Billion USD | 15.184% |